Skip to main content

Advertisement

SpringerLink
Log in

The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis

  • Research Article
  • Published:
Tumor Biology

Abstract

Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) plays an important role in tumor progression by helping tumor cell to escape from host immunological surveillance or modifying the characteristics of connective tissue around. RCAS1 may appropriately reflect the development and prognosis of tumor. In the study, we sought to identify the clinical significance of RCAS1 in colorectal cancer (CRC) diagnosis and tumor recurrence monitoring. Immunohistochemistry (IHC) with tissue array slides was preformed to analyze RCAS1 protein expression in CRC, colorectal polyps, and normal colon tissues. RCAS1 levels in colorectal cancer were significantly higher than those in colorectal polyps and normal colon tissues (P < 0.001). Silencing RCAS1 gene in human colonic adenocarcinoma cells decreased cell proliferation and enhanced apoptosis through the p53 signaling pathway. Further analysis by an enzyme-linked immunosorbent assay (ELISA) showed that serum RCAS1 levels in CRC are significantly higher than in healthy controls and polyps (P < 0.05), in which the highest serum RCAS1 level is reported in the recurrence group. The serum RCAS1 levels have a significant correlation with clinical stage and pathologic grading. Furthermore, the positive rate of serum RCAS1 in CRC was 82.1 %, which was higher than carcinoembryonic antigen (CEA). Especially in CEA-negative cases, the sensitivity of RCAS1 was 88.2 %. Finally, CRC patients who were followed up showed a serum RCAS1 level which significantly decreased after surgery (P < 0.001) and obviously increased in the recurrence group. Taken together, our data demonstrated that RCAS1 is not only a supplementary serological biomarker for CRC diagnosis but also useful for monitoring tumor recurrence. RCAS1 might be a supplementary serological marker for CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Cromheecke M, de Jong KP, Hoekstra HJ. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol. 1999;25:451–63.

    Article  CAS  PubMed  Google Scholar 

  4. EGTM. Tumour markers in gastrointestinal cancers—EGTM recommendations. European Group on Tumour Markers. Anticancer Res. 1999;19:2811–5.

    Google Scholar 

  5. ASCO. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997, by the American Society of Clinical Oncology. J Clin Oncol. 1998;16:793–5.

    Google Scholar 

  6. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow up of patients with colorectal cancer: a meta-analysis. Ann Surg. 1994;219:174–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Figueredo A, Rumble RB, Maroun J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26–39.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol. 2004;43(5):495–8.

    Article  CAS  PubMed  Google Scholar 

  9. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology. 2006;70(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  10. Kim HJ, Lee KW, Kim YJ, et al. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol. 2009;48(3):385–90.

    Article  CAS  PubMed  Google Scholar 

  11. Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer. 1996;77:1501–9.

    Article  CAS  PubMed  Google Scholar 

  12. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med. 1999;5:938–42.

    Article  CAS  PubMed  Google Scholar 

  13. Sonoda K, Miyamoto S, Nakashima M, Wake N. The biological role of unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci. 2008;13:1106–16.

    Article  CAS  PubMed  Google Scholar 

  14. Rousseau J, Têtu B, Caron D, Malenfant P, et al. RCAS1 is associated with ductal breast cancer progression. Biochem Biophys Res Commun. 2002;293:1544–9.

    Article  CAS  PubMed  Google Scholar 

  15. Kato H, Nakajima M, Masuda N, et al. Expression of RCASl in esophageal squamous cell carcinoma is associated with a poor prognosis. Surg Oncol. 2005;90(2):89–94.

    Article  CAS  Google Scholar 

  16. Nakamura Y, Yamazaki K, Oizami S, et al. Expression of RCASI in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci. 2004;95:260–5.

    Article  CAS  PubMed  Google Scholar 

  17. Okada K, Nakashima M, Komuta K, et al. Expression of human tumor associated antigen, RCASl, in human colorectal carcinoma and possible role in apoptosis of tumor infiltrating lymphocytes. Mod Pathol. 2003;16(7):679–85.

    Article  PubMed  Google Scholar 

  18. Aoki T, Inoue S, Imamura H, et al. EBAG9/RCASI expression in hepatocellular carcinoma: correlation with tumor dedifferentiation and proliferation. Eur J Cancer. 2003;39:1552–61.

    Article  CAS  PubMed  Google Scholar 

  19. Dutsch-Wicherek M, Wicherek L. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol. 2008;59:266–75.

    Article  PubMed  Google Scholar 

  20. Enjoji M, Noguchi K, Watanabe H, et al. A novel tumour marker RCAS1 in a case of extramammary Paget's disease. Clin Exp Dermatol. 2003;28:211–3.

    Article  CAS  PubMed  Google Scholar 

  21. Yoshida Y, Koga K, Watanabe T, et al. Potential utility of the tumour marker RCAS1 for monitoring patients with invasive extramammary Paget's disease. Acta Derm Venereol. 2008;88(3):296–7.

    PubMed  Google Scholar 

  22. Enjoji M, Nakamuta M, Yamaguchi K, et al. RCAS1, a useful serum marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer. Dig Dis Sci. 2004;49:1654–6.

    Article  PubMed  Google Scholar 

  23. Baek JY, Yeo HY, Chang HJ, Kim KH, Kim SY, Park JW, et al. Serpin B5 is a CEA-interacting biomarker for colorectal cancer. Int J Cancer. 2013. doi:10.1002/ijc.28494.

    PubMed  Google Scholar 

  24. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.

    Article  CAS  PubMed  Google Scholar 

  25. Sonoda K, Miyamoto S, Yamazaki A, Kobayashi H, Nakashima M, Mekada E, et al. Biologic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer. 2007;110:1979–90.

    Article  CAS  PubMed  Google Scholar 

  26. Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, et al. Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol. 2005;99:189–98.

    Article  CAS  PubMed  Google Scholar 

  27. Sonoda K, Miyamoto S, Yotsumoto F, et al. Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol Rep. 2007;17:623–8.

    CAS  PubMed  Google Scholar 

  28. Watanabe H, Enjoji M, Nakashima M, et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J Hepatol. 2003;39(4):559–63.

    Article  CAS  PubMed  Google Scholar 

  29. Leelawat K, Watanabe T, Nakajima M, et al. Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J Clin Pathol. 2003;56:764–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Coban S, Ozkan H, Köklü S, et al. The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol. 2006;20:593–6.

    PubMed Central  PubMed  Google Scholar 

  31. Tsujitani S, Saito H, Honboh T, et al. Prognostic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in relation to cadherin expression in patients with colorectal carcinoma. Dis Colon Rectum. 2007;50:1241–9.

    Article  PubMed  Google Scholar 

  32. Giaginis C, Margeli A, Kouraklis G, Zira A, Tsourouflis G, Theocharis S. Diagnostic and prognostic utility of serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) levels in colon cancer patients. Int J Biol Markers. 2009;24(2):70–6.

    CAS  PubMed  Google Scholar 

  33. Giaginis C, Giagini A, Theocharis S. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): a novel biomarker in the diagnosis and prognosis of human neoplasia. Histol Histopathol. 2009;24(6):761–76.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially supported by grant (SC1CA166016) from the National Institutes of Health (NIH).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China

    Su-xia Han, Li-juan Wang, Gui-hua Jin, Xia Ying, Chen-chen He, Xi-jing Guo, Ying Zhang & Qing Zhu

  2. Affiliated Hospital of Logistics University of Chinese People’s Armed Police Force, Tianjin, 300162, People’s Republic of China

    Jing Wang

  3. Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, 79968, USA

    Jian-ying Zhang

Authors
  1. Su-xia Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-juan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gui-hua Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xia Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chen-chen He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xi-jing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qing Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing Zhu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, Sx., Wang, J., Wang, Lj. et al. The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis. Tumor Biol. 35, 6149–6157 (2014). https://doi.org/10.1007/s13277-014-1814-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1814-3

Keywords

Search

Navigation